The three nicotinamide mononucleotide adenylyltransferase (NMNAT) family members 28 synthesize the electron carrier nicotinamide adenine dinucleotide (NAD + ) and are essential for 29 cellular metabolism. In mammalian axons, NMNAT activity appears to be required for axon 30 survival and is predominantly provided by NMNAT2. NMNAT2 has recently been shown to also 31 function as a chaperone to aid in the refolding of misfolded proteins. Nmnat2 deficiency in 32 mice, or in its ortholog dNmnat in Drosophila, results in axon outgrowth and survival defects. 33
48

INTRODUCTION 50
Fetal Akinesia Deformation Sequence (FADS) defines a broad range of disorders unified by 51 absent fetal movement resulting in secondary defects often leading to stillbirth or limited 52 postnatal survival 1; 2 F3165), mouse monoclonal anti-GFP clones 7.1 and 13.1 (1:2,000, Sigma-Aldrich 163 11814460001) and rabbit polyclonal α-Tubulin (1:7,500, Thermo Fisher Scientific PA5-29444). 164
Appropriate HRP-conjugated secondary antibodies were used for band detection with 165 SuperSignal™ West Dura Extended Duration Substrate (Thermo Fisher Scientific) using an 166
Alliance chemiluminescence imaging system (UVITEC Cambridge). Relative band intensities 167 on captured digital images were determined (area under histogram peaks) using Fiji software 168 (http://fiji.sc) 32 .
170
Microinjections and imaging. The preparation of dissociated SCG neuron cultures from wild-171 dithiothreitol. Luciferase activity was measured with the Luciferase Assay System (Promega, 232
Madison, WI, USA). 233
NMNAT2 was identified as the remaining candidate in an autosomal recessive model with two 323 unique alterations suggesting a compound heterozygous inheritance pattern (Supp Table 1) . 324
By co-segregation analysis, both parents were found to be heterozygous for one of the two 325 mutations identified in fetus 1. NMNAT2 was deemed clinically novel as no patients have been 326 identified to date but there is significant phenotypic overlap between the patient's phenotype 327 with a mouse model of NMNAT2 deficiency and the mutations are predicted to be damaging by 328 SIFT and Polyphen 21; 22 . When fetus 2 was diagnosed with such similar features, NMNAT2 329 was directly tested with Sanger sequencing and found to have the same compound 330 heterozygous variants. 331
332
NMNAT2 Variants 333
The maternally inherited variant was a single duplication of a cytosine at position 403 in exon 5 334 resulting in a frameshift and premature stop after 44 amino acids in NMNAT2 (c.403dupC, 335 p.Q135Pfs*44; confirmed by Sanger Sequencing; Fig. 2B,D) . The paternally inherited variant 336 was a missense mutation in exon 9 (c.695G>A, p.R232Q; confirmed by Sanger Sequencing; 337
Fig. 2B) resulting in a coding change of arginine to glutamine at position 232 (R232Q). 338
Conservation alignment shows R232 is highly conserved to D. melanogaster and has a 339 PhastCons score of 1 (Fig. 2C ). Multiple algorithms predict this to be damaging sequence 340 change (e.g.., PolyPhen score of 0.97, SIFT 0.0 and is predicted to be "disease causing" by 341
MutationTaster. The family has one unaffected daughter who was identified to carry only one 342 of the NMNAT2 mutations. This finding supports a recessive model in which both affected 343 alleles must be inherited in order to develop FADS.
Although the human NMNAT2 crystal structure has not been characterized, it is predicted that 345 the enzyme activity domains share the same structure folds as those of human NMNAT1 and 346 NMNAT3 38 . The R232 equivalent residue is invariant in all three human NMNAT isoforms and 347 NMNAT homologs across distant phyla (Fig. 2C) , suggesting its importance in protein function. 348
Given that the R232 residue is located within the conserved region, we examined the crystal 349 structure of human NMNAT1 to evaluate the potential structure-function consequences of the 350 R232Q mutation in NMNAT2 39 (Fig. 2E ). The residue is located at the end of a β strand 351 connecting the substrate binding domains for NMN and ATP, suggesting it is part of a 352 conformational change upon binding the adenine group of ATP substrate or NAD/NaAD 39 .
It is 353
(~70%) of neurites of the injected neurons for at least 24 hours after transection. Under these 368 conditions we found little or no preservation of cut neurites from SCG neurons injected with 369 either Flag-NMNAT2 R232Q or Flag-NMNAT2 Q135Pfs*44 expression vectors (Fig. 3A, B ). This lack 370 of protection is comparable to the lack of protection seen after injection with empty vector or 371 eGFP expression vector 20; 40 . 372 373 Importantly, even when using 2.5 times the vector concentration previously used in the 374
Wallerian degeneration assays, expression of the NMNAT2 Q135Pfs*44 variant was barely 375 detectable above background by Flag immunostaining in injected neurons (Fig. 3C) . In 376 contrast, robust expression of Flag-NMNAT2 R232Q was observed that closely matched that of 377
Flag-NMNAT2
WT (Fig. 3C ). Therefore, if the truncated Flag-NMNAT2 Q135Pfs*44 mutant retains 378 any functionality, its inability to protect transected neurites in this assay could simply reflect 379 very low levels of expression, whereas the failure of Flag-NMNAT2 R232Q to protect must 380 instead reflect either much more rapid loss of the mutant protein after injury relative to Flag-381 NMNAT2 WT , or a substantial loss of function. 382
383
NMNAT2
Q135Pfs*44 variant produces an unstable protein whereas NMNAT2 R232Q variant is 384 slightly more stable than wild-type NMNAT2 385
To investigate whether the stability of either variant Flag-NMNAT2 protein is altered relative to 386
Flag-NMNAT2
WT , we assessed their relative rates of turnover in transfected HEK 293T cells 387 after a protein synthesis block. Expression of the exogenous proteins was kept low to avoid 388 saturation of the degradation machinery. Levels of Flag-NMNAT2
WT and Flag-NMNAT2 R232Q at 389 the start of the protein synthesis block were comparable, whereas Flag-NMNAT2 Q135Pfs*44 levels were greatly reduced (Fig. 4A, B (Fig. 4C) . In broad agreement with 395 previous analyses, we saw almost complete loss of Flag-NMNAT2
WT within the 8 hour 396
timeframe of these assays with only ~25% remaining at 2 hours (Fig. 4A,D) 20; 40
. In 397 comparison, Flag-NMNAT2 Q135Pfs*44 was undetectable on blots even at 2 hours, even from the 398 highest starting levels (Fig 4C) , whereas significantly more Flag-NMNAT2 R232Q was detectable 399
Typically, this yielded ~2 mg of relatively pure recombinant protein per 0.5 L of bacterial culture 414 for both NMNAT2
WT and NMNAT2 R232Q ( Fig. 5A and 5B). Notably, the purified NMNAT2 was found to have NMNAT activity of just 0.51 ± 0.04 U/mg in these preparations compared to 416 11.2 ± 0.23 U/mg for purified NMNAT2 WT (Fig. 5C ). In contrast, NMNAT2 Q135Pfs*44 purifications 417 yielded 0.1 mg or less of protein per 0.5 L of bacterial culture with a ~22 kDa His-tagged 418 protein, corresponding in size to NMNAT2 Q135Pfs*44 , seemingly a relatively minor component of 419 the preparations (Fig. 5A and 5B). This is consistent with low level expression of the truncated 420 protein in bacteria, as in mammalian cells. While the highly heterogeneous NMNAT2 Q135Pfs*44
421
preparations did have detectable NMNAT activity, size-exclusion and ion exchange 422 chromatography revealed that none of the activity was associated with the 22 kDa protein 423 species (not shown). Instead, the invariant presence of a ~34 kDa protein recognized by both 424
anti-His and anti-NMNAT2 antibodies ( Fig. 5A and 5B), and thus likely to be His-tagged 425 NMNAT2 WT , probably accounts for any activity in these preparations. Although the origin of this 426 full-length protein remains unknown (correction of the frameshift mutation in the construct by 427 ribosomal frameshifting or transcriptional slippage in bacteria is one possibility), this analysis 428 suggests that the truncated NMNAT2 Q135Pfs*44 protein is inactive as expected. 429
430
The purity of NMNAT2 R232Q preparations allowed us to perform further characterization that 431 was not possible for NMNAT2 Q135Pfs*44 . NMNAT2
R232Q was eluted as a monomer following size-432 exclusion chromatography and was stable at -80 °C for months but was progressively 433 inactivated after thawing, similar to wild type NMNAT2 34; 41 . There was also a linear decline of 434 NMNAT activity for NMNAT2 R232Q at Mg 2+ concentrations above 5 mM (Fig. 5D ) so all 435 subsequent assays were performed at MgCl 2 concentrations only marginally exceeding theATP concentration (see Methods) thus avoiding the large excess of free Mg 2+ ions in solution 437 usually employed for assaying NMNAT2 WT 35; 36 . Further assays revealed a relative thermal 438 resistance and stability of NMNAT2 R232Q which showed a markedly higher residual activity, at 439 least relative to its lower baseline (Fig. 5C ), than NMNAT2
WT after 1 hour incubations at 440 temperatures ranging from 25 °C to 47 °C (Fig. 5E ) and, at ~40 min, the activity half-life of 441
NMNAT2
R232Q at 37 °C was more than twice that of NMNAT2 WT (Fig. 5F ). Nevertheless, the 442 optimum temperature for activity was the same for NMNAT2
WT and NMNAT2 R232Q (Fig. 5G) . 443
Crucially, however, the R232Q mutation had a profound negative effect on kinetic properties of 444 the enzyme: K cat was found to be reduced by ~20-fold and the Km values for NMN and ATP 445
were both increased ~10-fold (Table 2 ). These striking changes predict a ~200-fold reduced 446 catalytic efficiency (K cat /K m ) of NMNAT2 R232Q compared to NMNAT2 WT (Table 2 ). In fact, the 447 loss of catalytic activity may even be greater in vivo where physiological concentrations of ATP 448 (~1 mM) and NMN (5 µM) in brain predict a 500-fold or greater reduction compared to the wild 449 type enzyme 42 .
451
Together, these data suggest that both NMNAT2 R232Q and NMNAT2 Q135Pfs*44 have a substantial 452 loss of NMNAT activity. Although the R232Q mutation makes the enzyme slightly more 453 resistant to heat denaturation in vitro, any increased stability is likely to be completely negated 454 by the substantial detrimental effect it has on catalytic activity. In contrast, reduced 455 expression/stability and impaired catalytic activity (largely predicted from the absence of key C-456 terminal motifs resulting from truncation) likely combine to severely impair the activity of 457 To characterize the chaperone function, we used an in-cell luciferase refolding assay to 462 measure the ability of NMNAT isoforms to facilitate the refolding of unfolded luciferase after 463 heat shock 43; 44 (Fig. 6 ). Chaperones may act as "holdases" to protect their client protein from 464 unfolding, or as "foldases" to assist the folding to the native state 45; 46 . The in-cell luciferase-465 refolding assay allows the measurement of the luciferase unfolding after heat shock (red bars), 466 as well as the luciferase refolding after recovery (green bars) 43; 44 . We found that both 467
NMNAT2
WT and NMNAT2 R232Q greatly protected luciferase from unfolding during heat shock, 468
indicating strong "holdase" activity (Fig. 6, red bars) . However, when "foldase" activity was 469
analyzed, we found a remarkable loss of foldase activity specifically in NMNAT2 R232Q 470 expressing cells, while NMNAT2
WT facilitated the refolding of luciferase after heat shock, 471 comparable to heat shock protein 70 (Hsp70) and NMNAT3 (Fig. 6, green 
R232Q also consistently shows retarded migration during electrophoresis. While the 512 R232Q missense mutation could influence migration by altering the charge and/or structural 513 rigidity of the protein, the possibility that it might be the result of altered posttranslational 514 modification also needs to be considered, especially in the context of the loss-of-function and 515 increased stability of this variant. 516
517
The relative instability of the NMNAT2 Q135Pfs* variant protein largely precluded the same degree 518 of functional assessment. However, this instability is probably sufficient on its own to explain 519 the observed loss-of-function in our assays. Nevertheless, the fact that the frameshift mutation 520 results in a truncated protein lacking its entire C-terminal half, including many residues that are 521 critical for ATP binding, makes it extremely likely that NMNAT2 Q135Pfs*44 will also be defective 522 for NMNAT activity and chaperone function. Interestingly, because we expressed 523
NMNAT2
Q135Pfs*44 from an intronless construct in our assays, its relative instability likely reflects 524 an increased susceptibility of the truncated peptide to direct proteolytic cleavage. However, it 525 remains possible that nonsense mediated decay of the aberrant mRNA could also further limit 526 expression the FADS cases.Importantly, the FADS phenotype seen in the human patients shows broad overlap with that of 529 MNMAT2-deficient mice, in particular the severely reduced skeletal muscle mass and akinesia, 530 which are both likely due to failed peripheral innervation 21; 22 . However, the human cases and 531 the mouse model also show a number of notable differences. First, viability is further reduced 532 in humans; fetal patient demise occurs at around 27 weeks in gestation whereas MNMAT2-533 deficient mice die perinatally. Second, at least one patient developed hydrocephalus in which 534 the cortex was essentially spared. We do note Nmnat2 shows strong expression in the CNS 535 and PNS and therefore it is possible that Nmnat2 deficiency is related to the hydrocephlsus 50 . 536
Third, the bladder is consistently distended in the mouse model but we did not identify defects 537 in the bladder of either patient. Crucially, these differences could all be related to significantly 538 longer gestation and longer axons in humans than mice which likely allow for more severe 539 neurodegeneration in humans in utero and an increased likelihood of fetal demise 51 . In 540 addition, some symptoms specific to the human cases, including cystic hygroma, ascites, and 541 edema are likely to be a consequence of the fetal demise in utero. Interestingly, mice 542 nullizygous for other FADS-associated genes, such as Dok7 and Musk 52; 53 , have a phenotype 543 remarkably similar to MNMAT2-deficient mice, providing additional support for a direct link 544 between the NMNAT2 loss-of-function alleles in these cases and their FADS presentation. 545
546
There is strong evidence in the literature from several independent groups suggesting that 547 NMNAT2 enzymatic activity is the key activity for preventing activation of Wallerian-like axon 548 degeneration and that enzyme dead / chaperone competent mutants broadly fail to protect 549 axons 13 . At the moment it is not known whether NMNAT2 chaperone function also contributes 550 to axon protection and the finding that blocking the Wallerian degeneration pathway by 551 removal of SARM1 "fully" rescues axon defects and survival of mice lacking NMNAT2 552 suggests that chaperone activity is dispensable for survival or overt health in mice, at least in 553 the context of a relatively non-stressful home cage environment 26; 27 . However, as we found 554 the R232Q variant affects both chaperone and NAD synthase functions of NMNAT2, we 555 cannot definitively exclude a critical requirement for the chaperone function in human 556
development. 557 558
We conclude that the compound heterozygous variant NMNAT2 alleles in the FADS cases 559 described here encode proteins whose enzymatic and chaperone functions are both either 560 directly or indirectly impaired and are a likely underlying cause of the disorder. As in MNMAT2-561 deficient mice, we propose that defects in PNS axon outgrowth and/or survival primarily lead to 562 decreased innervation of the skeletal muscle in the fetuses resulting in severely reduced 563 skeletal muscle mass. We argue NMNAT2 may be added to the growing list of genes involved 564 in developing or maintaining PNS innervation that have been linked to FADS or FADS-565 associated symptoms such as DOK7, MUSK, RAPSN, ADCY6, GPR126, ECEL1, GLDN, and 566 PIEZO2 1 . NMNAT2 mutations should be investigated in other cases with fetal hydrops, fetal 567 akinesia, and widespread skeletal muscle deficiency. 568
It will also be important to determine whether more modest NMNAT2 loss-of-function alleles 569 are associated with other disorders. Interestingly, in the accompanying paper [Huppke et al;] , 570 another set of patients has been identified that are homozygous for a temperature-sensitive, 571 partial loss-of-function NMNAT2 allele who develop a childhood-onset peripheral neuropathy 572 less severe effect on NMNAT2 function leading to childhood or later-onset neuropathies, rather 574 than prenatal lethality, and/or preclinical phenotypes that predispose to adult-onset disorders. 575 576 577 578
Supplemental Data 579
Two tables with more information on variants identified in whole exome sequencing. ) were normalized to co-transfected eGFP and intensities at each 664 time point after emetine addition were calculated as a proportion of the intensity of the 0h,untreated band. Means ± SEM (n = 4) are plotted. n.s. = not significant (p > 0.05), ** p < 0.01 666 and *** p < 0.001, two-way ANOVA with Sidak's multiple comparisons test for effects between 667 variants. One-phase decay curves were fitted to the data sets for Flag-NMNAT2
WT and Flag-668 , which lacks the epitope recognized by the NMNAT2 680 antibody (raised against the C-terminus of the full-length protein), is expressed at a low level. 681
The NMNAT2 Q135Pfs*44 preparation contains a ~34 kDa protein recognized by both anti-His and 682
anti-NMNAT2 antibodies that is likely to be His-tagged NMNAT2 WT (red boxes). (C) NMNAT 683 specific activity of His-tag purified preparations measured at 37 °C with saturating 684 concentrations of substrates. The less pure NMNAT2 Q135Pfs*44 preparation is omitted despite 685 some activity found since it was not associated with the His-tagged 22 kDa truncated protein 686 . At 48 hrs 701 after transfection, protein synthesis was inhibited, and cells were subjected to heat shock at 42 702 °C for 45 mins, and then recovered at 37 °C for 3 hours. Quantification of luciferase activity 703 measured without heat shock (blue bars), after heat shock (red bards), and after recovery 704 (green bars). Luciferase activity in each group was normalized to no heat shock (set to 1). All 705 data were presented as mean ± SD, n=4. 
